These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 32900626)

  • 1. The prognosis and the impact of radiotherapy in clinically regional lymph node-positive prostate cancer: Which patients are candidates for local therapy with radiation?
    Ieiri K; Shiota M; Kashiwagi E; Takeuchi A; Takahashi R; Inokuchi J; Iwai H; Shiga KI; Yokomizo A; Yoshitake T; Shioyama Y; Ishigami K; Terashima H; Eto M
    Urol Oncol; 2020 Dec; 38(12):931.e1-931.e7. PubMed ID: 32900626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lactate Dehydrogenase Is a Serum Prognostic Factor in Clinically Regional Lymph Node-positive Prostate Cancer.
    Blas L; Shiota M; Yamada S; Ieiri K; Nagakawa S; Tsukahara S; Matsumoto T; Kashiwagi E; Takeuchi A; Inokuchi J; Shiga KI; Yokomizo A; Eto M
    Anticancer Res; 2021 Aug; 41(8):3885-3889. PubMed ID: 34281850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Value of Lower Tract Urinary Symptoms in Clinically Regional Lymph Node-positive Prostate Cancer.
    Blas L; Ieiri K; Shiota M; Nagakawa S; Tsukahara S; Matsumoto T; Kashiwagi E; Takeuchi A; Inokuchi J; Shiga KI; Yokomizo A; Eto M
    Anticancer Res; 2021 Nov; 41(11):5593-5598. PubMed ID: 34732430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Whole pelvis radiotherapy for pathological node-positive prostate cancer : Oncological outcome and prognostic factors.
    Poelaert F; Fonteyne V; Ost P; De Troyer B; Decaestecker K; De Meerleer G; De Visschere P; Claeys T; Dhondt B; Lumen N
    Strahlenther Onkol; 2017 Jun; 193(6):444-451. PubMed ID: 28101585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of Outcomes in Patients With Clinically Lymph Node Positive Prostate Cancer After Definitive Radiotherapy.
    Kim TH; Kim DY; Kim JS
    In Vivo; 2023; 37(5):2365-2370. PubMed ID: 37652494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of adjuvant radiotherapy in pathologically lymph node-positive prostate cancer.
    Jegadeesh N; Liu Y; Zhang C; Zhong J; Cassidy RJ; Gillespie T; Kucuk O; Rossi P; Master VA; Alemozaffar M; Jani AB
    Cancer; 2017 Feb; 123(3):512-520. PubMed ID: 27859018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sentinel Lymph Node Dissection to Select Clinically Node-negative Prostate Cancer Patients for Pelvic Radiation Therapy: Effect on Biochemical Recurrence and Systemic Progression.
    Grivas N; Wit E; Pos F; de Jong J; Vegt E; Bex A; Hendricksen K; Horenblas S; KleinJan G; van Rhijn B; van der Poel H
    Int J Radiat Oncol Biol Phys; 2017 Feb; 97(2):347-354. PubMed ID: 28068243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of prostate carcinoma death in patients with lymph node metastasis.
    Cheng L; Zincke H; Blute ML; Bergstralh EJ; Scherer B; Bostwick DG
    Cancer; 2001 Jan; 91(1):66-73. PubMed ID: 11148561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of clinical staging algorithms and 111indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients.
    Polascik TJ; Manyak MJ; Haseman MK; Gurganus RT; Rogers B; Maguire RT; Partin AW
    Cancer; 1999 Apr; 85(7):1586-92. PubMed ID: 10193950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Adjuvant Radiotherapy in Node-positive Prostate Cancer Patients: The Importance of Patient Selection.
    Abdollah F; Dalela D; Sood A; Keeley J; Alanee S; Briganti A; Montorsi F; Peabody JO; Menon M
    Eur Urol; 2018 Sep; 74(3):253-256. PubMed ID: 29720348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen receptor expression in prostate cancer lymph node metastases is predictive of outcome after surgery.
    Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Cheng L; Bostwick DG
    J Urol; 1999 Apr; 161(4):1233-7. PubMed ID: 10081876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of lymph node metastasis and its impact on long-term prognosis in clinically localized prostate cancer.
    Arai Y; Kanamaru H; Yoshimura K; Okubo K; Kamoto T; Yoshida O
    Int J Urol; 1998 Sep; 5(5):459-65. PubMed ID: 9781435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term Results of External Beam Radiotherapy for Prostate Cancer with Prostate-specific Antigen of More Than 50 ng/ml and Without Evidence of Lymph Node or Distant Metastasis.
    Umezawa R; Inaba K; Nakamura S; Wakita A; Okamoto H; Shima S; Tsuchida K; Kashihara T; Kobayashi K; Harada K; Takahashi K; Murakami N; Ito Y; Igaki H; Jingu K; Itami J
    Anticancer Res; 2018 Apr; 38(4):2303-2309. PubMed ID: 29599353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. External beam radiotherapy for clinically node-negative, localized hormone-refractory prostate cancer: impact of pretreatment PSA value on radiotherapeutic outcomes.
    Akimoto T; Kitamoto Y; Saito J; Harashima K; Nakano T; Ito K; Yamamoto T; Kurokawa K; Yamanaka H; Takahashi M; Mitsuhashi N; Niibe H
    Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):372-9. PubMed ID: 15145150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. External beam radiotherapy for clinically localized hormone-refractory prostate cancer: clinical significance of Nadir prostate-specific antigen value within 12 months.
    Ogawa K; Nakamura K; Sasaki T; Onishi H; Koizumi M; Shioyama Y; Araya M; Mukumoto N; Mitsumori M; Teshima T;
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(3):759-65. PubMed ID: 19327908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term use of combined radiation therapy and hormonal therapy in the management of stage D1 prostate cancer.
    Robnett TJ; Whittington R; Malkowicz SB; Brereton HD; Van Arsdalen K; Drach G; Wein AJ
    Int J Radiat Oncol Biol Phys; 2002 Aug; 53(5):1146-51. PubMed ID: 12128114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Favorable outcomes in locally advanced and node positive prostate cancer patients treated with combined pelvic IMRT and androgen deprivation therapy.
    Lilleby W; Narrang A; Tafjord G; Vlatkovic L; Russnes KM; Stensvold A; Hole KH; Tran P; Eilertsen K
    Radiat Oncol; 2015 Nov; 10():232. PubMed ID: 26577452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes of definitive whole pelvic radiotherapy for clinical lymph node metastatic prostate cancer.
    Tsuchida K; Inaba K; Kashihara T; Murakami N; Okuma K; Takahashi K; Igaki H; Nakayama Y; Maejima A; Shinoda Y; Matsui Y; Komiyama M; Fujimoto H; Ito Y; Sumi M; Nakano T; Itami J
    Cancer Med; 2020 Sep; 9(18):6629-6637. PubMed ID: 32750234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Number of metastatic lymph nodes as determinant of outcome after salvage radical prostatectomy for radiation-recurrent prostate cancer.
    Gugliemetti G; Sukhu R; Conca Baenas MA; Meeks J; Sjoberg DD; Eastham JA; Scardino PT; Touijer K
    Actas Urol Esp; 2016 Sep; 40(7):434-9. PubMed ID: 27184342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.